All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
ovarian cancer (OC), immune chekpoint inhibitors vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMagyn-050 (all population), 2021 0.96 [0.74; 1.25]
IMagyn-050 (PDL1 >1%), 2021 0.98 [0.68; 1.41]
0.97 [0.78 ; 1.20 ] IMagyn-050 (all population), 2021, IMagyn-050 (PDL1 >1%), 2021 2 0% 2,085 low not evaluable progression or deaths (PFS)detailed results IMagyn-050 (all population), 2021 0.92 [0.79; 1.07]
IMagyn-050 (PDL1 >1%), 2021 0.80 [0.65; 0.99]
0.88 [0.77 ; 1.00 ] IMagyn-050 (all population), 2021, IMagyn-050 (PDL1 >1%), 2021 2 10% 2,085 low not evaluable objective responses (ORR)detailed results IMagyn-050 (all population), 2021 1.65 [0.88; 3.08]
IMagyn-050 (PDL1 >1%), 2021 1.35 [0.63; 2.91]
1.52 [0.94 ; 2.47 ] IMagyn-050 (all population), 2021, IMagyn-050 (PDL1 >1%), 2021 2 0% 817 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 1.00 [0.02; 50.63]
1.00 [0.02 ; 50.63 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.52 [0.49; 13.03]
2.52 [0.49 ; 13.03 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.01 [0.07; 59.96]
2.01 [0.07 ; 59.96 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 1.00 [0.06; 16.07]
1.00 [0.06 ; 16.07 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 1.76 [0.51; 6.05]
1.76 [0.51 ; 6.05 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 3.02 [0.31; 29.10]
3.02 [0.31 ; 29.10 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.01 [0.07; 59.96]
2.01 [0.07 ; 59.96 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 0.50 [0.02; 14.97]
0.50 [0.02 ; 14.97 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 6.04 [0.30; 120.87]
6.04 [0.30 ; 120.87 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Nephritis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.01 [0.07; 59.96]
2.01 [0.07 ; 59.96 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 8.07 [0.43; 152.94]
8.07 [0.43 ; 152.94 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.01 [0.07; 59.96]
2.01 [0.07 ; 59.96 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Rash TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 1.59 [0.61; 4.12]
1.59 [0.61 ; 4.12 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMagyn-050 (all population), 2021 7.25 [3.06; 17.21]
7.25 [3.06 ; 17.21 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.01 [0.37; 11.03]
2.01 [0.37 ; 11.03 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 0.83 [0.25; 2.75]
0.83 [0.25 ; 2.75 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 2.52 [0.49; 13.03]
2.52 [0.49 ; 13.03 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Hypertension AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 0.88 [0.67; 1.16]
0.88 [0.67 ; 1.16 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 3.03 [0.61; 15.06]
3.03 [0.61 ; 15.06 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable Proteinuria AE (grade 3-4)detailed results IMagyn-050 (all population), 2021 0.60 [0.31; 1.18]
0.60 [0.31 ; 1.18 ] IMagyn-050 (all population), 2021 1 0% 1,286 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 08:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 7,248,247,249,250,251,246
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743